Background Quality of life (QOL) is a critical factor in decision-making for advanced breast
cancer (ABC). There is a need to improve how QOL and treatment-related side effects (SEs) …

Background: A cyclin-dependent kinase 4/6 inhibitor (CDK4/6i)+ endocrine therapy is
recommended as first-line treatment for hormone receptor-positive/human epidermal growth …

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the standard agents for treating
patients with estrogen receptor-positive and human epidermal growth factor receptor 2 …

Objective To map the evidence available in the literature on the health-related quality of life
of women with breast cancer using hormone therapy. Data sources This review followed the …

We thank the correspondents for their complimentary and thoughtful response to our indirect
comparison of quality-of-life scores between patients with advanced breast cancer receiving …

We have read with great and sincere interest the paper by Law et al. reporting an indirect
comparison of patients' reported outcomes (PRO) in the Paloma-3 and Monarch-2 studies …

Conclusion Many thanks to all our Editorial Board members, authors and reviewers who
work with us on JCER. I look forward to welcoming more readers to the journal now that all …